

ERA[®] is a diagnostic test patented by Igenomix in 2009



3 in every 10 patients have a displaced WOI

ERA analyzes 248 genes related to endometrial receptivity

pET | Personalized Embryo Transfer


www.igenomix.com

| | pET CLINICAL OUTCOME | | |
|-------------------------|----------------------|-----------------|-----------------|
| | RECEPTIVE | CORRECTION | TOTAL |
| NUMBER OF PET PERFORMED | 215 | 297 | 512 |
| IMPLANTATION RATE | 56.3% (166/295) | 58.2% (216/371) | 57.4% (382/666) |
| PREGNANCY RATE | 73% (157/215) | 72.7% (216/297) | 72.9% (373/512) |
| BIOCHEMICAL PREGNANCY | 9.6% (15/157) | 10.6% (23/216) | 10.2% (38/373) |
| MISCARRIAGE | 11.5% (18/157) | 12% (26/216) | 11.8% (44/373) |
| ECTOPIC | 0.6% (1/157) | 0.5% (1/216) | 0.5% (2/373) |
| ONGOING / PREGNANCY | 78.3% (123/157) | 76.9% (166/216) | 77.5% (289/373) |
| ONGOING / PET | 57.2% (123/215) | 55.9% (166/297) | 56.4% (289/512) |


ERA[®] Results

Personalized embryo transfer (pET) according to ERA[®]

Indicated for recurrent implantation failure (RIF)



- Days with ESTRADIOL VALERATE
- Days with PROGESTERONE



Why choose Igenomix ERA test?



- **ERA is backed by 33 publications** 29 from Igenomix and 4 external publications.



- Randomized study in progress to assess its **applicability in patients without any prior ART.**

(ClinicalTrials.gov Identifier: NCT01954758)



- **Algorithms based on machine learning technologies.**



- **ERA allows clinicians to identify transition phases with 12 hours shifts.**

When is a second biopsy needed?

90 % of cases don't need a second biopsy. The second biopsy is only required under two circumstances:

- Patients with a "Pre-receptive 2 days" result.
- Patients with a "Post-receptive" result.

IGENOMIX DATA

